Different brands of tirzepatide: what exists, what's licensed, and what the names mean

You searched for 'different brands of tirzepatide' (here's the honest picture

Picture this: you've been reading about tirzepatide results, maybe on a US health forum or a newspaper article, and suddenly there are two or three names floating around) Mounjaro, Zepbound, perhaps something else entirely. It's genuinely confusing, because the molecule is the same but the names, the packaging and crucially the regulatory status are not.

Tirzepatide is the international non-proprietary name, the molecule's official scientific name. Pharmaceutical companies brand that molecule differently in different countries. In the UK and across most of Europe, Eli Lilly markets tirzepatide as Mounjaro. That is the brand name you will see on a pen dispensed by any legitimate UK pharmacy, including a GPhC-registered service like ours. You can read a thorough overview of the medicine itself on the tirzepatide overview page.

In the United States, Eli Lilly sells a separate presentation of tirzepatide under the brand name Zepbound, licensed specifically for weight management by the FDA. Zepbound does not exist as a UK product. It has no UK marketing authorisation. If someone offers you Zepbound from a UK seller, that product has not been through MHRA review in that form and should not be trusted. This is not a technicality, it is the legal and safety position.

There is also Mounjaro licensed for type 2 diabetes in the UK, which is the same pen, same strengths, same Eli Lilly supply chain, the distinction is the indication on the licence, not a different product. The NHS medicines page for tirzepatide on nhs.uk covers both indications clearly.

Why the same molecule carries different brand names in different countries

Pharmaceutical companies apply for regulatory approval country by country, or in the case of the EU via the European Medicines Agency. The MHRA is the regulator for the UK. Each authority assesses clinical trial data, manufacturing standards and labelling requirements independently, and each can approve a product under whatever brand name the company chooses for that market.

Eli Lilly chose Mounjaro for both the UK and EU weight-management licence. They chose Zepbound for the US weight-management launch. For the diabetes indication in the US, they use Mounjaro too, same brand as here. None of this changes the underlying pharmacology, but it does mean that looking up 'Zepbound dosing' or 'Zepbound side effects' from a US source may give you information that doesn't map neatly onto the UK product, the UK titration schedule, or the clinical expectations set by a UK prescriber.

If you're curious about how the naming conventions work in more depth, the page on tirzepatide's different names goes further into the terminology, and tirzepatide name brands covers the brand landscape in a structured way.

It's also worth knowing that research into next-generation medicines in this class (such as retatrutide, which adds a third receptor pathway) means new names will emerge. A comparison of how retatrutide differs from tirzepatide covers what's in development versus what's available now.

Counterfeit and unregulated tirzepatide: why brand names are used to mislead

The MHRA has been explicit: fake weight-loss pens are circulating in the UK, sold through social media and unverified online sellers. Some carry convincing-looking branding. In late 2025, authorities raided the first illicit UK manufacturing site producing counterfeit tirzepatide pens, seizing around 20 million doses of illegally traded weight-loss medicines worth approximately £45 million. Fake pens have in some cases contained insulin rather than the stated medicine, a serious and potentially life-threatening substitution.

The 'different brand' angle matters here because some sellers use the US brand name Zepbound, or invent plausible-sounding names, to make their product seem legitimate or imported from a regulated market. Neither Zepbound nor any other tirzepatide brand beyond Mounjaro is legally available from a UK pharmacy. If a seller cannot point you to their entry on the GPhC register (verifiable at the GPhC pharmacy register) treat that as a red flag. Equally, if a product is offered without a prescription following a clinical assessment, walk away. You can report suspect sellers to the MHRA's Yellow Card scheme.

Our pharmacy's GPhC registration number is 9012878, verifiable directly on the register. Every medicine we dispense comes through the licensed UK supply chain.

Practical implications: what to check before starting treatment in the UK

If you're considering tirzepatide for weight management in the UK, the relevant questions are straightforward. Is the pharmacy GPhC-registered? Is there a genuine clinical assessment (carried out by a named prescriber, not automated software) before any medicine is supplied? Is the product Mounjaro, from the licensed UK supply chain?

At our clinical team, consultations are reviewed personally by a GPhC-registered Independent Prescriber the same day they arrive. Identity and weight are verified; your answers are read by a clinician who makes a clinical judgement, not a system that ticks boxes. If you order before noon on a working day and your consultation is approved, your treatment goes out that afternoon via DPD and arrives the next working day in plain, unmarked packaging. No surprises before breakfast.

Costs, what's included in the price, and how to compare what's on offer from different providers are covered on the Mounjaro price comparison page. If you'd like a broader look at treatment options alongside tirzepatide, the weight-loss overview sets out what's available and who each option suits.

When you're ready, check your eligibility and start your free consultation, a prescriber will take it from there.